In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...

Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help ...

Germinal centers are high-speed evolution machines. Tiny clusters in the lymph nodes, germinal centers refine antibodies ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

Climb Bio (NASDAQ:CLYM – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.15) ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...